|
|
Fall is living up to its name here on the south coast of BC; not one, but two powerful ‘bomb’ cyclones swooped in and then stalled off the coast. Winds were still strong enough to rattle the leaves off the trees in the past week. Also moving in, the province’s latest pandemic plans. The BC government has unveiled a new booster strategy as we move forward. Vaccinations for children under 12y old are coming and soon, and Life Sciences BC platinum sponsor, Pfizer received FDA approval in this age group for the Pfizer/BioNTech vaccine based around homegrown Acuitas delivery technology. |
|
Congratulations also to Provincial Health Services Authority clinician, Dr. John Webb who received a prestigious Canadian Cardiovascular Society Achievement Award. The award recognizes many decades or contributions to the field of cardiology. Dr. Webb is on faculty as the McLeod Professor of Heart Valve Innovation with LSBC member, UBC Faculty of Medicine. He’s also the medical chair of the Transcatheter Heart Valve Program with Cardiac Services BC, and medical director of the Catheterization Lab at St. Paul's Hospital.
Next week, I’m looking forward to two days of premier pitching. Held on Wednesday, November 3 and Thursday, November 4, Invest in BC presented by Lumira Ventures, is one of our investment-and innovation-focused signature events. Throughout the year, these events raise the life sciences profile at home and abroad to encourage investment and global partnering opportunities. This year, we have 31 investor-ready companies presenting their pitches. Session details are now available on the event website, and there is still time to register for a ticket.
-Wendy and the LSBC team
|
|
|
|
On Wednesday, October 27, industry leaders gathered for an innovative panel discussion to share strategies and tactics on how to choose a translational oncology indication in research and development, what data drives that choice, and they discussed how any potential pitfalls could be avoided. READ MORE
|
|
|
|
Minimally invasive image-guided therapy start-up, SpinaFX Medical Inc. is pleased to announce the signing of a commercialization contract manufacturing agreement with StarFish Product Engineering Inc., Canada’s largest medical device design, development, and manufacturing services organization. READ MORE
|
|
|
|
Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, is pleased to announce that it has recently received a CAD$2M cash payment from a refundable tax credit program from its clinical research work in Australia, which brings Algernon’s current working capital balance to approximately CAD$3.5M. READ MORE
|
|
|
|
GenEp, Inc., a biotechnology company developing therapies that address unmet needs in patients with epilepsy, announced today the closing of a $1.45 million seed financing. The financing was co-led by the UVA Licensing & Ventures Group Seed Fund, Angelini Lumira Biosciences Fund and 3B Future Health Fund, with additional participation by the Virginia Innovation Partnership Corporation, Kids Connect Charitable Fund, PDI Ventures and the company’s management team. READ MORE
|
|
|
|
Frazier was selected by an independent committee of distinguished peer CEOs, who recognize his leadership at Merck driving transformation and growth to help produce powerful results for patients, stakeholders and society. READ MORE
|
|
|
|
NervGen Pharma Corp., a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, today announced the formation of its Spinal Cord Injury Clinical Advisory Board comprised of five world-class scientific and clinical researchers in the field of spinal cord injury: Drs. James Guest, Steven Kirshblum, Brian Kwon, Linda Jones and Daniel Lammertse. READ MORE
|
|
|
|
Rhineland-Palatinate Minister President Malu Dreyer was on hand as Boehringer Ingelheim opened a new tablet production facility in Ingelheim on October 27. Starting immediately, the Solids Launch Factory will manufacture all the company’s new drugs introduced in tablet form (solids). The facility will employ around 75 workers. Total investments in the plant amount to EUR 90 million. READ MORE
|
|
|
|
The Health Research Foundation (HRF) of Innovative Medicines Canada is pleased to announce that Dr. Brianne Wood has been awarded the Fellowship in Health Systems Resilience. Dr. Wood is an Associate Scientist, Social Accountability and Learning Health Systems at the Northern Ontario School of Medicine University and the Thunder Bay Regional Health Sciences Centre. READ MORE
|
|
|
|
Evonik has signed a purchase agreement to acquire the Swiss plant extract producer Botanica, with closing expected in November. With its presence in Switzerland, France and Germany, Botanica is a European leader in sustainable botanical extracts for the personal care industry. Botanica will be integrated into the Care Solutions business line within Evonik’s life sciences division Nutrition & Care. READ MORE
|
|
|
|
RepliCel Life Sciences Inc., a company developing next-generation technologies in aesthetics and orthopedics, announced on October 28 the DermaPrecise trademark for its dermal injector product portfolio. READ MORE
|
|
|
|
We are publicly calling for new proposals related to drug development research as part our efforts for open innovation, to promote pharmaceutical research and development through enhanced cooperation with universities, research institutes, and enterprises around the world. READ MORE
|
|
|
|
The DeepDyve Digital Library: a platform that is designed to make it easy and affordable for research organizations to discover, access, organize, and collaborate on peer-reviewed papers. But it’s an innovation that was nearly a decade in the making. READ MORE
|
|
 |
HDR designs academic, bioengineering, biotechnology, pharmaceutical and other corporate facilities that reflect a deep understanding of the full spectrum of research requirements. The facilities they design are flexible to accommodate inevitable technological, process and workflow changes. They design spaces to promote knowledge transfer essential to scientific advancement. These facilities, in turn, are used to attract and retain top-tier talent. Ultimately, HDR's goal is to help accelerate the time from discovery to preventative, curative and transformational solutions that improve lives.
|
|
|
|
Farabloc technology presents a New Alternative Pain Relief System. As an electromagnetic shielding fabric, Farabloc contains extremely fine stainless steel fibers and nylon, with an appearance similar to linen. This drug-free product has a significant shielding effect on high-frequency electromagnetic fields (EMF) while permitting low-frequency EMF through, which affects cell membrane. Farabloc has been extensively researched and is successfully used by many people in dealing with conditions causing chronic pain, such as phantom limb pain, osteoarthritis, carpal tunnel syndrome, sports-related muscle soreness, fibromyalgia, and reflex sympathetic disorder.
|
|
|
|
|
|
PERSPECTIVES ON GLOBAL HEALTHCARE INNOVATION |
What’s driving innovation in life science and healthcare? SVB is committed to serving the ecosystem by providing industry-leading reports featuring proprietary analysis and targeted outlooks to help companies and investors achieve their goals. Twice a year we publish deep-dive analyses describing fundraising, investment, M&A and IPO activity of private, venture-backed biopharma, medical device and diagnostic/tools companies. Our deep relationships with top life science and healthcare entrepreneurs and investors inform our insights and give us a vantage point unlike any other bank. To find out more about Silicon Valley Bank click here. |
|
This successful candidate for this role will be a highly motivated and creative electrophysiologist who will contribute to characterizing and elucidating the effects of novel agents on the function of target ion channels.
|
|
In this position you will support the day-to-day operational needs of the Zymeworks’ Business Systems team for multiple hosted applications for Quality, Clinical and Regulatory Enterprise Applications with a focus on control, security, technical support, accessibility of SharePoint Online and enterprise document management.
|
|
Symvivo is seeking a highly motivated and creative Research Associate with proven industrial experience in Recombinant Protein Expression and Analysis to join our dynamic and diverse R&D team.
|
|
|
|
Post A Job on the LSBC Website! |
LSBC Membership Discounts on Job Postings
As an LSBC member, your first five job postings EARNS a free repost on BioTalent Canada's The Petri Dish. After your first five reposts, you will also receive 25% off all job postings on The Petri Dish. Want more info? Contact Peter McLoughlin - talent@lifesciencesbc.ca
|
|
|
|
|
|
|
